Category: Peptide Q&A
-
What is the current status of NAD+ supplementation in clinical trials for treating age-related macular degeneration or diabetic retinopathy?
What is the current status of NAD+ supplementation in clinical trials for treating age-related macular degeneration or diabetic retinopathy?
-
How do the effects of oral NAD+ precursors compare to intravenous NAD+ infusions in terms of cognitive enhancement and fatigue reduction in clinical populations?
How do the effects of oral NAD+ precursors compare to intravenous NAD+ infusions in terms of cognitive enhancement and fatigue reduction in clinical pop
-
What are the cost-effectiveness and accessibility considerations for long-term NAD+ supplementation, especially in low-resource healthcare settings?
What are the cost-effectiveness and accessibility considerations for long-term NAD+ supplementation, especially in low-resource healthcare settings?
-
Is there evidence that NAD+ supplementation can exacerbate pre-existing conditions such as cancer or autoimmune disorders, particularly in high-dose regimens?
Is there evidence that NAD+ supplementation can exacerbate pre-existing conditions such as cancer or autoimmune disorders, particularly in high-dose reg
-
What is the role of NAD+ in promoting axonal regeneration in peripheral nerve injury, and how does it influence Schwann cell function and myelination?
What is the role of NAD+ in promoting axonal regeneration in peripheral nerve injury, and how does it influence Schwann cell function and myelination?
-
Can NAD+ supplementation mitigate the effects of chronic fatigue syndrome by restoring mitochondrial energy production in skeletal muscle and neural tissue?
Can NAD+ supplementation mitigate the effects of chronic fatigue syndrome by restoring mitochondrial energy production in skeletal muscle and neural tis
-
How does NAD+ influence the balance between neuroprotective and neurotoxic pathways in the context of stroke and traumatic brain injury?
How does NAD+ influence the balance between neuroprotective and neurotoxic pathways in the context of stroke and traumatic brain injury?